The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.128.10.1207

Since methvldopa has been classified as a central nervous system depressant that produces tranquilization and reversible extrapyramidal symptoms, as well as reducing central amines, it has been suggested that it might have an antipsychotic potential. The authors' study showed a statistically significant deterioration in patients treated with methyldopa as compared with those treated with methotrimeprazine; however, five patients showed some improvement on methyldopa. It is suggested that methyldopa's lack of general antipsychotic activity is related to the reduced dopamine concentration in the brain instead of an increased turnover rate, which is characteristic of more effective neuroleptic drugs.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.